Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 14 | 2021 | 1268 | 3.920 |
Why?
|
| Transplantation, Heterologous | 7 | 2022 | 363 | 2.560 |
Why?
|
| Graft Survival | 14 | 2022 | 884 | 2.000 |
Why?
|
| Thrombocytopenia | 4 | 2022 | 183 | 1.960 |
Why?
|
| Living Donors | 7 | 2021 | 339 | 1.940 |
Why?
|
| Kidney Transplantation | 12 | 2018 | 849 | 1.910 |
Why?
|
| Liver | 6 | 2022 | 1230 | 1.620 |
Why?
|
| Hepatectomy | 3 | 2017 | 166 | 1.550 |
Why?
|
| Nephrectomy | 4 | 2018 | 294 | 1.290 |
Why?
|
| Tissue Scaffolds | 2 | 2017 | 106 | 1.120 |
Why?
|
| Hepatitis C | 3 | 2021 | 208 | 1.010 |
Why?
|
| Swine | 11 | 2022 | 555 | 0.910 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2022 | 12 | 0.840 |
Why?
|
| Graft Rejection | 9 | 2021 | 1065 | 0.820 |
Why?
|
| Pancreas Transplantation | 2 | 2012 | 103 | 0.800 |
Why?
|
| Kidney Failure, Chronic | 3 | 2016 | 509 | 0.770 |
Why?
|
| Kidney Diseases | 3 | 2015 | 418 | 0.770 |
Why?
|
| Galactosyltransferases | 3 | 2017 | 40 | 0.760 |
Why?
|
| Donor Selection | 2 | 2017 | 67 | 0.710 |
Why?
|
| Immunosuppressive Agents | 3 | 2014 | 977 | 0.690 |
Why?
|
| Fluid Therapy | 2 | 2018 | 50 | 0.690 |
Why?
|
| Heat Stroke | 1 | 2018 | 9 | 0.680 |
Why?
|
| Lung Transplantation | 2 | 2017 | 175 | 0.670 |
Why?
|
| Multiple Organ Failure | 1 | 2018 | 53 | 0.660 |
Why?
|
| Waiting Lists | 2 | 2020 | 175 | 0.650 |
Why?
|
| Heterografts | 2 | 2017 | 98 | 0.640 |
Why?
|
| Animals, Genetically Modified | 5 | 2022 | 181 | 0.630 |
Why?
|
| Neuraminic Acids | 1 | 2017 | 10 | 0.630 |
Why?
|
| Postoperative Complications | 5 | 2019 | 2207 | 0.610 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2017 | 78 | 0.590 |
Why?
|
| Lecithin Cholesterol Acyltransferase Deficiency | 1 | 2016 | 3 | 0.590 |
Why?
|
| Bile Ducts | 1 | 2016 | 59 | 0.590 |
Why?
|
| End Stage Liver Disease | 1 | 2017 | 61 | 0.580 |
Why?
|
| Laparoscopy | 3 | 2018 | 754 | 0.570 |
Why?
|
| Tissue Engineering | 1 | 2017 | 181 | 0.540 |
Why?
|
| Tissue and Organ Procurement | 3 | 2020 | 311 | 0.540 |
Why?
|
| Hemofiltration | 1 | 2015 | 11 | 0.540 |
Why?
|
| Retrospective Studies | 13 | 2021 | 8489 | 0.520 |
Why?
|
| Intraoperative Care | 1 | 2015 | 82 | 0.510 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2014 | 6 | 0.490 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 394 | 0.490 |
Why?
|
| Male | 22 | 2020 | 40965 | 0.480 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 212 | 0.470 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 81 | 0.460 |
Why?
|
| Hemostasis, Surgical | 1 | 2013 | 26 | 0.450 |
Why?
|
| Humans | 30 | 2022 | 86643 | 0.450 |
Why?
|
| Immunoconjugates | 1 | 2014 | 106 | 0.450 |
Why?
|
| Membrane Cofactor Protein | 3 | 2017 | 10 | 0.440 |
Why?
|
| Adult | 14 | 2020 | 25648 | 0.430 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 267 | 0.430 |
Why?
|
| Gene Knockout Techniques | 3 | 2017 | 77 | 0.430 |
Why?
|
| Intensive Care Units | 1 | 2015 | 373 | 0.420 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 295 | 0.400 |
Why?
|
| Transplantation, Homologous | 7 | 2017 | 996 | 0.390 |
Why?
|
| Female | 18 | 2020 | 44532 | 0.380 |
Why?
|
| Thymus Gland | 5 | 2004 | 195 | 0.370 |
Why?
|
| Survival Rate | 5 | 2019 | 1863 | 0.360 |
Why?
|
| Middle Aged | 14 | 2020 | 25028 | 0.350 |
Why?
|
| Diabetic Nephropathies | 1 | 2012 | 248 | 0.340 |
Why?
|
| Animals | 15 | 2022 | 26582 | 0.330 |
Why?
|
| Rats, Wistar | 2 | 2017 | 297 | 0.290 |
Why?
|
| Extracorporeal Circulation | 2 | 2017 | 26 | 0.280 |
Why?
|
| Tissue Donors | 2 | 2020 | 463 | 0.250 |
Why?
|
| Biopsy | 2 | 2017 | 1163 | 0.230 |
Why?
|
| Risk Factors | 6 | 2020 | 5417 | 0.220 |
Why?
|
| Clodronic Acid | 1 | 2022 | 9 | 0.210 |
Why?
|
| Heme Oxygenase-1 | 1 | 2022 | 19 | 0.210 |
Why?
|
| Perfusion | 1 | 2022 | 203 | 0.200 |
Why?
|
| Hematopoiesis | 1 | 2002 | 163 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 860 | 0.200 |
Why?
|
| Time Factors | 5 | 2020 | 5210 | 0.190 |
Why?
|
| Renin | 1 | 2020 | 79 | 0.190 |
Why?
|
| Angiotensin II | 1 | 2020 | 94 | 0.190 |
Why?
|
| Vasoconstrictor Agents | 1 | 2020 | 53 | 0.190 |
Why?
|
| Hepatitis C, Chronic | 1 | 2021 | 126 | 0.180 |
Why?
|
| Reoperation | 3 | 2012 | 597 | 0.180 |
Why?
|
| Papio | 2 | 2014 | 82 | 0.180 |
Why?
|
| Shock, Septic | 1 | 2020 | 102 | 0.180 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 133 | 0.170 |
Why?
|
| CD55 Antigens | 2 | 2017 | 20 | 0.170 |
Why?
|
| T-Lymphocytes | 2 | 2003 | 1195 | 0.170 |
Why?
|
| Liver Failure, Acute | 1 | 2018 | 38 | 0.170 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 160 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2020 | 238 | 0.160 |
Why?
|
| Kupffer Cells | 1 | 2017 | 13 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 257 | 0.160 |
Why?
|
| Respiratory Insufficiency | 1 | 2019 | 150 | 0.150 |
Why?
|
| Hernia, Umbilical | 1 | 2017 | 17 | 0.150 |
Why?
|
| Craniocerebral Trauma | 1 | 2017 | 52 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 3640 | 0.150 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 139 | 0.150 |
Why?
|
| Cell Tracking | 1 | 2016 | 14 | 0.150 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 48 | 0.150 |
Why?
|
| Hepatocytes | 1 | 2017 | 127 | 0.150 |
Why?
|
| Hospital Mortality | 1 | 2019 | 349 | 0.150 |
Why?
|
| Cell Compartmentation | 1 | 2016 | 69 | 0.150 |
Why?
|
| Fatal Outcome | 1 | 2017 | 293 | 0.150 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 63 | 0.150 |
Why?
|
| Social Support | 1 | 2018 | 193 | 0.140 |
Why?
|
| Albumins | 1 | 2016 | 133 | 0.140 |
Why?
|
| Inflammation | 1 | 2022 | 920 | 0.140 |
Why?
|
| Immune Tolerance | 3 | 2004 | 337 | 0.140 |
Why?
|
| Heart Arrest | 1 | 2019 | 265 | 0.140 |
Why?
|
| Sildenafil Citrate | 1 | 2015 | 22 | 0.130 |
Why?
|
| Maryland | 1 | 2015 | 35 | 0.130 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2015 | 9 | 0.130 |
Why?
|
| Cell Lineage | 1 | 2016 | 273 | 0.130 |
Why?
|
| Violence | 1 | 2017 | 143 | 0.130 |
Why?
|
| Animals, Newborn | 1 | 2016 | 510 | 0.130 |
Why?
|
| Risk Assessment | 4 | 2020 | 2261 | 0.130 |
Why?
|
| Robotics | 1 | 2018 | 267 | 0.130 |
Why?
|
| Aged | 3 | 2017 | 18415 | 0.130 |
Why?
|
| Endothelial Cells | 1 | 2017 | 428 | 0.130 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 1753 | 0.130 |
Why?
|
| Comorbidity | 1 | 2018 | 943 | 0.120 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2016 | 136 | 0.120 |
Why?
|
| von Willebrand Factor | 1 | 2014 | 37 | 0.120 |
Why?
|
| Endoscopy | 1 | 2017 | 332 | 0.120 |
Why?
|
| Abatacept | 1 | 2014 | 83 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 2 | 2015 | 384 | 0.120 |
Why?
|
| Length of Stay | 2 | 2016 | 702 | 0.120 |
Why?
|
| Organ Transplantation | 1 | 2017 | 265 | 0.120 |
Why?
|
| Ligation | 1 | 2013 | 51 | 0.120 |
Why?
|
| Patient Selection | 1 | 2017 | 685 | 0.110 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 297 | 0.110 |
Why?
|
| Histocompatibility | 3 | 2017 | 71 | 0.110 |
Why?
|
| Swine, Miniature | 5 | 2003 | 51 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 999 | 0.110 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2818 | 0.110 |
Why?
|
| Kidney | 4 | 2015 | 1241 | 0.100 |
Why?
|
| Heart Transplantation | 1 | 2017 | 705 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1169 | 0.100 |
Why?
|
| C-Peptide | 1 | 2012 | 174 | 0.100 |
Why?
|
| Wisconsin | 1 | 2011 | 39 | 0.100 |
Why?
|
| Rats | 1 | 2017 | 3990 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2020 | 7993 | 0.100 |
Why?
|
| DNA | 1 | 2016 | 1294 | 0.100 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1578 | 0.100 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2002 | 225 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2705 | 0.090 |
Why?
|
| Islets of Langerhans | 2 | 2002 | 544 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 859 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2011 | 971 | 0.080 |
Why?
|
| Biomarkers | 1 | 2014 | 1718 | 0.080 |
Why?
|
| Incidence | 1 | 2011 | 1577 | 0.070 |
Why?
|
| Young Adult | 1 | 2018 | 5976 | 0.070 |
Why?
|
| Disease Progression | 1 | 2011 | 1531 | 0.070 |
Why?
|
| Pancreatectomy | 2 | 2002 | 148 | 0.060 |
Why?
|
| Prognosis | 1 | 2011 | 3679 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2011 | 4213 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1801 | 0.050 |
Why?
|
| Transplantation Tolerance | 1 | 2003 | 130 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 98 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2021 | 159 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2001 | 373 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2002 | 873 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2021 | 510 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 567 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 814 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2018 | 237 | 0.040 |
Why?
|
| Wound Healing | 1 | 2018 | 344 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2018 | 240 | 0.030 |
Why?
|
| Patient Safety | 1 | 2018 | 212 | 0.030 |
Why?
|
| Operative Time | 1 | 2016 | 127 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 112 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1673 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 244 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2016 | 157 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2015 | 118 | 0.030 |
Why?
|
| Transplantation, Heterotopic | 2 | 2003 | 45 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 455 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 329 | 0.030 |
Why?
|
| United States | 1 | 2020 | 6672 | 0.020 |
Why?
|
| Insulin | 2 | 2002 | 1160 | 0.020 |
Why?
|
| Immunotoxins | 1 | 2003 | 14 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2003 | 74 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2003 | 81 | 0.010 |
Why?
|
| Surgically-Created Structures | 1 | 2002 | 5 | 0.010 |
Why?
|
| Omentum | 1 | 2003 | 71 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2003 | 234 | 0.010 |
Why?
|
| Creatinine | 1 | 2003 | 338 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2002 | 303 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2002 | 176 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 350 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2001 | 154 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2001 | 158 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2001 | 203 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 916 | 0.010 |
Why?
|
| Haplotypes | 1 | 2001 | 642 | 0.010 |
Why?
|